BR100 Increased By (1.36%)
BR30 Increased By (1.41%)
KSE100 Increased By (1.18%)
KSE30 Increased By (1.25%)
AGHA 7.88 Increased By ▲ 0.13 (1.68%)
BECO 5.22 Increased By ▲ 0.03 (0.58%)
BML 58.80 Increased By ▲ 0.14 (0.24%)
BOP 34.45 Increased By ▲ 0.76 (2.26%)
CNERGY 10.92 Increased By ▲ 0.31 (2.92%)
CSIL 5.44 Increased By ▲ 0.14 (2.64%)
FCCL 54.80 Increased By ▲ 1.06 (1.97%)
FFL 16.71 Increased By ▲ 0.25 (1.52%)
FNEL 1.22 No Change ▼ 0.00 (0%)
KEL 7.45 Increased By ▲ 0.17 (2.34%)
KOSM 5.68 Increased By ▲ 0.04 (0.71%)
LOTCHEM 29.90 Increased By ▲ 0.25 (0.84%)
MLCF 97.15 Increased By ▲ 0.79 (0.82%)
NBP 205.90 Increased By ▲ 2.37 (1.16%)
NCPL 57.97 Increased By ▲ 1.12 (1.97%)
NPL 69.00 Increased By ▲ 1.69 (2.51%)
OGDC 320.90 Increased By ▲ 2.68 (0.84%)
PACE 10.70 Increased By ▲ 0.07 (0.66%)
PAEL 43.10 Increased By ▲ 1.33 (3.18%)
PIBTL 17.10 Increased By ▲ 0.29 (1.73%)
PPL 223.64 Increased By ▲ 3.47 (1.58%)
PRL 52.14 Increased By ▲ 3.09 (6.3%)
PTC 71.05 Increased By ▲ 1.04 (1.49%)
SSGC 29.58 Increased By ▲ 0.44 (1.51%)
TBL 9.90 Increased By ▲ 0.13 (1.33%)
TELE 9.02 Increased By ▲ 0.20 (2.27%)
TPL 17.75 Increased By ▲ 0.58 (3.38%)
TPLP 13.07 Increased By ▲ 0.56 (4.48%)
TREET 22.95 Increased By ▲ 0.36 (1.59%)
TRG 60.83 Increased By ▲ 0.61 (1.01%)
By

Swiss drugmaker Roche Holding AG plans to sell its 800-employee drug manufacturing plant in Vacaville, California, or it will shut the factory by 2029, according to e-mailed letters to workers seen by Reuters on Wednesday.

In a statement, Roche confirmed the divestiture plan for the site, which makes monoclonal antibodies from genetically modified living cells, but did not address the potential closing of the plant or its timeline.

The company said in the statement it does not expect to need the very large volumes of the medicines the plant provides, and large-scale production will be done in one of the company’s newer plants.

It also plans to focus on drugs targeting smaller patient populations moving forward and to draw on a range of biotechnology methods beyond monoclonal antibodies, it said, adding there would be no impact to operations or employees at this time.

Roche is under new leadership this year after CEO Thomas Schinecker took the helm and Teresa Graham became head of the pharmaceuticals division in March.

The Swiss group is under pressure to develop new treatments to offset the loss of billions in sales due to cheap biotech copies of its established cancer medicines Herceptin, Avastin and Rituxan, some of which are made in Vacaville.

GSK Pakistan recognised as ‘top employer’

It is also contending with dipping revenue for its COVID-19 therapies and tests.

The company said it is seeking a buyer that will continue to use the plant as an operating facility. If the company is unable to find a buyer, it will ramp down production and close the plant in 2028 to 2029, the emails said.

Roche acquired the plant more than a decade ago with its purchase of US biotech Genentech.

The plant makes drugs for cancer including Avastin and Herceptin, as well as Actemra for rheumatoid arthritis. During the pandemic, Roche collaborated with Regeneron Pharmaceuticals to increase supply of that drugmaker’s COVID-19 antibody treatment.

Roche manufactured the treatment at the Vacaville plant, which it sells outside the US under the brand name Ronapreve.

Comments

Comments are closed for this article.